User:Superlark/sandbox

Catalent, Inc. (Catalent Pharma Solutions) is a global provider of advanced drug delivery technology and development solutions for drugs, biologics and consumer health products. Headquartered in Somerset, New Jersey, Catalent operates 30 locations across five continents, producing more than 70 billion doses annually for nearly 7,000 customer products.

Originally created through a series of acquisitions by Cardinal Health Inc., Catalent became independent in 2007. Catalent’s oral, injectable and respiratory delivery technologies address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. Catalent promotes its ability to increase customer’s speed to market and participation in nearly half of new drug entities approved by the Food and Drug Administration in the last decade. The company currently holds more than 1,300 patents & applications and continues to expand its offerings through investments in emerging technologies. In its fiscal year 2014 (ending June 30), Catalent’s customers included 83 of the top 100 branded drug marketers, 20 of the top 25 generics marketers, 38 of the top 50 biologics marketers, and 19 of the top 20 consumer health marketers globally. On July 31, 2014, Catalent became a public company and is listed on the New York Stock Exchange (NYSE: CTLT).

Before 2007
In 1996, Cardinal Health acquired PCI (Headquarters: Philadelphia, Pennsylvania). PCI (Packaging Coordinators Inc.) is a pharmaceutical contract packing service for commercial and clinical packaging. In 1998, Cardinal Health acquired R.P. Scherer Corporation (Headquarters: Troy, Michigan). Robert Pauli Scherer founded the R.P. Scherer Corporation to commercialize his innovation of softgel encapsulation using the rotary die production process. In 1999, Cardinal Health acquired Automatic Liquid Packaging, Inc. (Headquarters: Woodstock, Ill.), whose Blow-Fill-Seal Technology allowed Cardinal to enter the sterile product market. Cardinal Health also acquired International Processing Corporation (Headquarters: Winchester, Kentucky) for its advanced controlled drug release and coating manufacturing expertise.

In 2002, Cardinal Health acquired Magellan Laboratories Inc., a company that specialized in product development expertise. In 2003, Cardinal Health acquired Gala Biotech (Headquarters: Middleton, Wisconsin). Gala Biotech had established technologies surrounding gene insertion and the production of pharmaceutical proteins, which became GPEx® Technology. In the same year, Cardinal Health also acquired Intercare Group PLC, broadening its global capabilities in Europe. In 2004-2006, Cardinal Health further expanded its reach in biotechnology and pharmaceutical markets through multiple other acquisitions.

Formation of Catalent in 2007
In 2007, the Pharmaceutical Technologies and Services segment of Cardinal Health was purchased by Blackstone Group and re-branded as Catalent Pharma Solutions.

After 2007 and Initial Public Offering
In 2011, the Company acquired the molecular optimization platform OptiForm®, from GlaxoSmithKline. In 2012, Catalent acquired Aptuit, a clinical supply solutions company. As part of the deal, Catalent gained three sites in the United States, two sites in the United Kingdom and one in Singapore. Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany. In 2013, Catalent Pharmaceutical Solutions continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology Co., a China-based company, and Relthy Laboratories in Brazil. Also in 2013, Catalent created a new business unit, Advanced Delivery Technologies which focuses on innovative and proven drug delivery technologies, optimizing the company’s multiple technologies, cross-platform R&D solutions and global commercial manufacturing network. This is the current structure of Catalent’s business which includes softgel technologies, advanced delivery technologies and development & clinical services business units.

Catalent announced its initial public offering on July 30, 2014. After raising more than $870 million, Catalent became a publicly traded company on the New York Stock Exchange (NYSE). The company priced its 42.5 million shares of common stock at $20.50 apiece, with a market capitalization of $2.4 billion. The shares began trading on the NYSE on July 31, 2014, under the ticker symbol CTLT, and the offering closed on August 1, 2014. The proceeds of the offering went to the redemption of more than $800 million of Catalent’s outstanding debt. “This will allow the company to significantly reduce its interest expense, enable future potential internal and external growth strategies, and to continue our growth-biased investments into new technologies, capabilities, global development and manufacturing facilities and capacity,” a company statement reported.

Drug Delivery Technologies
Catalent's brand currently owns and operates the following drug delivery technologies:

Predevelopment Technologies
 * Optiform® Technology
 * Catalent Micron Technologies

Oral Drug Delivery Technologies
 * RP Scherer Softgel Technology
 * OptiGel™ Technology
 * OptiGel™ Lock Technology
 * OptiGel™ Micro Technology
 * OptiGel™ Mini Technology
 * Zydis® Technology
 * OSDrC® OptiDose™ Drug Delivery Technology
 * OptiMelt™ Technology
 * OptiPact™ Technology

Sterile Technologies
 * ADVASEPT™ Technology

Biologics
 * SMARTag™ Technology
 * GPEx® Technology

Centers of Excellence
Catalent has designated the following locations as a Center of Excellence with the following specializations:


 * Swindon, United Kingdom – Zydis® Technology
 * Somerset, New Jersey – OSDrC® OptiDose™ Drug Delivery Technology
 * Philadelphia, Pennsylvania – Clinical Supply Services
 * St. Petersburg, Florida – RP Scherer Softgel Technology
 * Winchester, Kentucky – OptiMelt™ Technology
 * Madison, Wisconsin – GPEx® Technology
 * Research Triangle Park, North Carolina – Inhalation